• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

核受体共抑制因子(NCoR)是宫颈癌的一个预后良好的标志物。

Nuclear receptor corepressor (NCoR) is a positive prognosticator for cervical cancer.

机构信息

Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University of Munich, Maistrasse 11, 80337, Munich, Germany.

Department of Pathology, LMU Munich, Thalkirchner Street 56, 80337, Munich, Germany.

出版信息

Arch Gynecol Obstet. 2021 Nov;304(5):1307-1314. doi: 10.1007/s00404-021-06053-3. Epub 2021 Apr 16.

DOI:10.1007/s00404-021-06053-3
PMID:33861372
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8490237/
Abstract

PURPOSE

Enzymes with epigenetic functions play an essential part in development of cancer. However, the significance of epigenetic changes in cervical carcinoma as a prognostic factor has not been fully investigated. Nuclear receptor corepressor (NCoR) presents itself as a potentially important element for epigenetic modification and as a potential prognostic aspect in cervical cancer.

METHODS

By immunohistochemical staining of 250 tumor samples, the expression strength of NCoR was measured and evaluated by immunoreactive score (IRS) in the nucleus and cytoplasm.

RESULTS

A low expression of NCoR in our patients was a disadvantage in overall survival. Expression of NCoR was negatively correlated with viral oncoprotein E6, acetylated histone H3 acetyl K9 and FIGO status, and positively correlated to p53.

CONCLUSIONS

Our study has identified epigenetic modification of tumor cells thus seems to be of relevance in cervical cancer as well for diagnosis, as a marker or as a potential therapeutic target in patients with advanced cervical carcinoma.

摘要

目的

具有表观遗传功能的酶在癌症的发展中起着至关重要的作用。然而,表观遗传变化在宫颈癌作为预后因素的意义尚未得到充分研究。核受体辅抑制因子(NCoR)作为表观遗传修饰的潜在重要因素和宫颈癌的潜在预后因素。

方法

通过对 250 个肿瘤样本的免疫组织化学染色,用免疫反应评分(IRS)测量细胞核和细胞质中 NCoR 的表达强度。

结果

我们的患者中 NCoR 的低表达在总生存中是不利的。NCoR 的表达与病毒癌蛋白 E6、乙酰化组蛋白 H3 乙酰 K9 和 FIGO 状态呈负相关,与 p53 呈正相关。

结论

我们的研究已经确定了肿瘤细胞的表观遗传修饰,因此在宫颈癌的诊断、作为标志物或作为晚期宫颈癌患者的潜在治疗靶点方面似乎具有相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e815/8490237/f5676c2e678b/404_2021_6053_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e815/8490237/bc066b3ca7e6/404_2021_6053_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e815/8490237/bbc77e4488a8/404_2021_6053_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e815/8490237/f5676c2e678b/404_2021_6053_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e815/8490237/bc066b3ca7e6/404_2021_6053_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e815/8490237/bbc77e4488a8/404_2021_6053_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e815/8490237/f5676c2e678b/404_2021_6053_Fig3_HTML.jpg

相似文献

1
Nuclear receptor corepressor (NCoR) is a positive prognosticator for cervical cancer.核受体共抑制因子(NCoR)是宫颈癌的一个预后良好的标志物。
Arch Gynecol Obstet. 2021 Nov;304(5):1307-1314. doi: 10.1007/s00404-021-06053-3. Epub 2021 Apr 16.
2
Histone H3 Acetyl K9 and Histone H3 Tri Methyl K4 as Prognostic Markers for Patients with Cervical Cancer.组蛋白H3乙酰化赖氨酸9和组蛋白H3三甲基化赖氨酸4作为宫颈癌患者的预后标志物
Int J Mol Sci. 2017 Feb 23;18(3):477. doi: 10.3390/ijms18030477.
3
Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.环氧化酶-2转录受人类乳头瘤病毒16型E6和E7癌蛋白调控:共抑制因子/共激活因子交换的证据
Cancer Res. 2007 Apr 15;67(8):3976-85. doi: 10.1158/0008-5472.CAN-06-4273.
4
Human papilloma virus early proteins E6 (HPV16/18-E6) and the cell cycle marker P16 (INK4a) are useful prognostic markers in uterine cervical carcinomas in Qassim Region--Saudi Arabia.人乳头瘤病毒早期蛋白E6(HPV16/18 - E6)和细胞周期标志物P16(INK4a)是沙特阿拉伯卡西姆地区子宫颈癌有用的预后标志物。
Pathol Oncol Res. 2015 Jan;21(1):157-66. doi: 10.1007/s12253-014-9801-y. Epub 2014 Jun 13.
5
Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis.核共抑制因子1表达的自调节环控制侵袭、肿瘤生长和转移。
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):E328-37. doi: 10.1073/pnas.1520469113. Epub 2016 Jan 4.
6
Berberine alters epigenetic modifications, disrupts microtubule network, and modulates HPV-18 E6-E7 oncoproteins by targeting p53 in cervical cancer cell HeLa: a mechanistic study including molecular docking.小檗碱通过靶向宫颈癌 HeLa 细胞中的 p53 改变表观遗传修饰、破坏微管网络并调节 HPV-18 E6-E7 癌蛋白:包括分子对接的机制研究。
Eur J Pharmacol. 2014 Dec 5;744:132-46. doi: 10.1016/j.ejphar.2014.09.048. Epub 2014 Oct 18.
7
Expression of estrogen receptor co-regulators NCoR and PELP1 in epithelial cells and myofibroblasts of colorectal carcinomas: cytoplasmic translocation of NCoR in epithelial cells correlates with better [corrected] prognosis.雌激素受体共调节因子NCoR和PELP1在结直肠癌上皮细胞和成肌纤维细胞中的表达:上皮细胞中NCoR的细胞质易位与更好的[校正后]预后相关。
Virchows Arch. 2009 Jan;454(1):41-53. doi: 10.1007/s00428-008-0708-4. Epub 2008 Dec 2.
8
The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.浸润性宫颈癌患者宫颈阴道涂片中人乳头瘤病毒16/18 E6、p53和Bcl-2蛋白的存在情况。
Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):329-35.
9
Immunohistochemical Evaluation of E6/E7 HPV Oncoproteins Staining in Cervical Cancer.宫颈癌中E6/E7人乳头瘤病毒癌蛋白染色的免疫组织化学评估
Anticancer Res. 2016 Jun;36(6):3195-8.
10
HPV-mediated nuclear export of HP1γ drives cervical tumorigenesis by downregulation of p53.HPV 介导的 HP1γ 核输出通过下调 p53 驱动宫颈癌发生。
Cell Death Differ. 2020 Sep;27(9):2537-2551. doi: 10.1038/s41418-020-0520-5. Epub 2020 Mar 23.

引用本文的文献

1
SPOP promotes cervical cancer progression by inducing the movement of PD-1 away from PD-L1 in spatial localization.SPOP 通过诱导 PD-1 在空间定位上远离 PD-L1,促进宫颈癌的进展。
J Transl Med. 2022 Aug 30;20(1):384. doi: 10.1186/s12967-022-03574-6.
2
Compatibility of ingredients of Danshen (Radix ) and Honghua () and their protective effects on cerebral ischemia-reperfusion injury in rats.丹参和红花成分的配伍及其对大鼠脑缺血再灌注损伤的保护作用。
Exp Ther Med. 2021 Aug;22(2):849. doi: 10.3892/etm.2021.10281. Epub 2021 Jun 8.

本文引用的文献

1
Evolution of NCoR-1 and NCoR-2 corepressor alternative mRNA splicing in placental mammals.胎盘哺乳动物中NCoR-1和NCoR-2共抑制因子可变mRNA剪接的进化
BMC Res Notes. 2019 Jun 17;12(1):343. doi: 10.1186/s13104-019-4384-z.
2
Different expression of GSK3β and pS9GSK3β depending on phenotype of cervical cancer: possible association of GSK3β with squamous cell carcinoma and pS9GSK3β with adenocarcinoma.根据宫颈癌的表型,GSK3β和pS9GSK3β表达不同:GSK3β可能与鳞状细胞癌相关,而pS9GSK3β与腺癌相关。
Obstet Gynecol Sci. 2019 May;62(3):157-165. doi: 10.5468/ogs.2019.62.3.157. Epub 2019 Apr 12.
3
Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer.
RIP140和LCoR作为宫颈癌预后不良独立标志物的研究
Oncotarget. 2017 Oct 31;8(62):105356-105371. doi: 10.18632/oncotarget.22187. eCollection 2017 Dec 1.
4
The involvement of E6, p53, p16, MDM2 and Gal-3 in the clinical outcome of patients with cervical cancer.E6、p53、p16、MDM2和Gal-3在宫颈癌患者临床结局中的作用。
Oncol Lett. 2017 Oct;14(4):4467-4476. doi: 10.3892/ol.2017.6752. Epub 2017 Aug 14.
5
Histone H3 Acetyl K9 and Histone H3 Tri Methyl K4 as Prognostic Markers for Patients with Cervical Cancer.组蛋白H3乙酰化赖氨酸9和组蛋白H3三甲基化赖氨酸4作为宫颈癌患者的预后标志物
Int J Mol Sci. 2017 Feb 23;18(3):477. doi: 10.3390/ijms18030477.
6
Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts.刺猬信号通路抑制增强了放疗和顺铂对原位宫颈癌异种移植瘤的疗效。
Br J Cancer. 2017 Jan 3;116(1):50-57. doi: 10.1038/bjc.2016.383. Epub 2016 Nov 22.
7
Immunohistochemical Evaluation of E6/E7 HPV Oncoproteins Staining in Cervical Cancer.宫颈癌中E6/E7人乳头瘤病毒癌蛋白染色的免疫组织化学评估
Anticancer Res. 2016 Jun;36(6):3195-8.
8
Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.癌症中的核受体共抑制复合物:机制、功能与调控
Am J Clin Exp Urol. 2014 Oct 2;2(3):169-87. eCollection 2014.
9
Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions.HPV 诱导的宫颈前病变中(表观)遗传改变的临床意义。
Nat Rev Cancer. 2014 Jun;14(6):395-405. doi: 10.1038/nrc3728.
10
Filling a gap in cervical cancer screening programmes.填补宫颈癌筛查项目中的空白。
Lancet Oncol. 2014 Mar;15(3):249-51. doi: 10.1016/S1470-2045(14)70073-7. Epub 2014 Feb 13.